David Matthew Wilson

USPTO Granted Patents = 27 (Patent Applications = 8)

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 4.5

ph-index = 7

Forward Citations = 140(Granted Patents)

Location History:

Herts, GB (2006)
Harlow, GB (2007 - 2012)
Stevenage, GB (2014 - 2018)
Madrid, ES (2019 - 2020)

Company Filing History:

Smithkline Beecham Corporation

patents

3 out of 230

Glaxosmithkline Intellectual Property Development Limited

Smithkline Beechum P.l.c.

patents

Years Active: 2006-2020

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10815218 - Benzoimidazole derivatives as PAD4 inhibitors (2020-10-27),

2. 10407407 - Benzoimidazole derivatives as PAD4 inhibitors (2019-09-10),

3. 10039755 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2018-08-07),

4. 9833449 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2017-12-05),

5. 9624219 - Compound (S) and (R)-N-(2-fluoropyridin-4-yl)-3-methyl-2-(5-methyl-2,4-dioxo-1,2-dihydropyrido[3,4-d]pyrimidin-3(4H)-yl)butanamide and use (2017-04-18),

6. 9518054 - 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors (2016-12-13),

7. 9447074 - Compounds (2016-09-20),

8. 9127003 - 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors (2015-09-08),

9. 8993560 - Compounds (2015-03-31),

10. 8697725 - Tetrahydroquinoline derivatives and their pharmaceutical use (2014-04-15),

11. 8691747 - Method of treatment based on ATAD2 inhibitors (2014-04-08),

12. 8633319 - 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors (2014-01-21),

13. 8207331 - Benzazepine derivatives for the treatment of neurological disorders (2012-06-26),

14. 7888347 - Pyrazolo [3,4-D]azepine derivatives as histamine H3 antagonists (2011-02-15),

15. 7799773 - Benzazepine derivatives for the treatment of neurological disorders (2010-09-21),

Title: David Matthew Wilson: Innovator in Pharmaceutical Patents

Introduction

David Matthew Wilson, a prominent inventor based in Harlow, GB, has made significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 27 patents, Wilson's work primarily focuses on developing compounds that offer therapeutic benefits for various medical conditions. His innovative approach has contributed to advancements in treatment options.

Latest Patents

Among his latest inventions are benzoimidazole derivatives that serve as inhibitors of PAD4 (Peptidylarginine deiminase type 4). These compounds, defined by a specific structure (formula I), have been identified as potential treatments for diverse disorders, including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis. The therapeutic potential of these compounds extends the possibilities for managing complex health issues.

Career Highlights

David Matthew Wilson's career includes roles at esteemed organizations such as Glaxo Group Limited and SmithKline Beecham Corporation. His time at these companies has equipped him with a wealth of experience in pharmaceutical research and development, further solidifying his status as a key innovator in the industry. His work has not only advanced the understanding of drug development but also highlighted the importance of novel therapeutic pathways.

Collaborations

Throughout his career, Wilson has collaborated with notable colleagues, including David Kenneth Dean and Michael David Barker. These partnerships have fostered a collaborative environment that encourages innovation and the exchange of ideas, leading to impactful advancements in their respective fields.

Conclusion

David Matthew Wilson stands out as a significant figure in the realm of pharmaceutical inventions. His extensive patent portfolio and dedication to discovering new treatment options underscore his commitment to improving patient outcomes. As he continues to innovate, the medical community and patients alike can look forward to the advancements that his work will undoubtedly bring.

This text is generated by artificial intelligence and may not be accurate.